rs16894846
This variant is located in the GRM4 gene.
▶Research that mentions this SNP (1)
▶Genome-wide genotype-based risk model for survival in core binding factor acute myeloid leukemia patientsAssociationN=104Silvia Park et al.(2018)· Annals of Hematology
This genome-wide SNP association study in 104 core binding factor acute myeloid leukemia (CBF-AML) patients developed predictive risk models for overall survival (OS) and event-free survival (EFS) incorporating six SNPs each combined with clinical factors. The OS model significantly stratified patients into low- and high-risk groups with 3-year survival rates of 80.4% vs 22.0% (p=8.75×10⁻¹³), while the EFS model achieved 75.0% vs 17.1% (p=5.95×10⁻¹³), demonstrating that genome-wide SNP genotyping can improve survival prediction in CBF-AML beyond conventional clinical factors.
About GRM4
L-glutamate is the major excitatory neurotransmitter in the central nervous system and activates both ionotropic and metabotropic glutamate receptors. Glutamatergic neurotransmission is involved in most aspects of normal brain function and can be perturbed in many neuropathologic conditions. The metabotropic glutamate receptors are a family of G protein-coupled receptors, that have been divided into 3 groups on the basis of sequence homology, putative signal transduction mechanisms, and pharmacologic properties. Group I includes GRM1 and GRM5 and these receptors have been shown to activate phospholipase C. Group II includes GRM2 and GRM3 while Group III includes GRM4, GRM6, GRM7 and GRM8. Group II and III receptors are linked to the inhibition of the cyclic AMP cascade but differ in their agonist selectivities. Several transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Feb 2012]
View all GRM4 variants →Gene information from NCBI Gene. Variant classifications from ClinVar.
Community Wiki
No community notes yet for this variant. Sign in to start one.
Comments
Sign in to join the discussion.
Loading comments…